Director Robert Califf resigns from Centessa board to become FDA Commissioner

Centessa Pharmaceuticals plc

Robert M. Califf, M.D., resigned from Centessa's Board effective Feb 16, 2022.
Resignation due to his confirmation as incoming FDA Commissioner; not a disagreement.
Dr. Califf is no longer a member of the Board or any committees.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert M. Califf, M.D.

Director

CNTA · Centessa Pharmaceuticals plc

Effective: 2022-02-16
Filed: February 16, 2022, 6:59 PM ET

On February 16, 2022, Robert M. Califf, M.D., a member of the Board of Directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company” or “Centessa”), notified the Company of his resignation from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert M. Califf, M.D. resigned as Director at Centessa Pharmaceuticals plc.

Action: resigned
Role: Director

Exact text from the filing

On February 16, 2022, Robert M. Califf, M.D., a member of the Board of Directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company” or “Centessa”), notified the Company of his resignation from the Board, effective immediately.

View on SEC.gov

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-22-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.